MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
19.02
-0.34 (-1.76%)
Jul 24, 2026, 4:00 PM EDT - Market closed
MoonLake Immunotherapeutics Employees
MoonLake Immunotherapeutics had 130 employees as of December 31, 2025. The number of employees increased by 30 or 30.00% compared to the previous year.
Employees
130
Change (1Y)
30
Growth (1Y)
30.00%
Revenue / Employee
n/a
Profits / Employee
-$1,977,546
Market Cap
1.57B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 130 | 30 | 30.00% |
| Dec 31, 2024 | 100 | 50 | 100.00% |
| Dec 31, 2023 | 50 | 30 | 150.00% |
| Dec 31, 2022 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| Ascentage Pharma Group International | 767 |
| Recursion Pharmaceuticals | 600 |
| AbCellera Biologics | 562 |
| Intellia Therapeutics | 377 |
| Zymeworks | 243 |
| Innoviva | 159 |
| Maze Therapeutics | 141 |
MLTX News
- 4 weeks ago - MoonLake Immunotherapeutics 9M share Secondary priced at $20.00 - TheFly
- 4 weeks ago - MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering - GlobeNewsWire
- 4 weeks ago - MoonLake Immunotherapeutics announces $150M offering of Class A ordinary shares - TheFly
- 4 weeks ago - MoonLake Immunotherapeutics Announces Proposed Public Offering - GlobeNewsWire
- 4 weeks ago - MoonLake’s SLK has ‘blockbuster potential,’ says Clear Street - TheFly
- 4 weeks ago - MoonLake Immunotherapeutics Transcript: Investor Day 2026 - Transcripts
- 4 weeks ago - MoonLake Immunotherapeutics Slides: FY 2026 - Filings
- 5 weeks ago - MoonLake announces Week 52 results of Phase 3 VELA-1, VELA-2 trials - TheFly